Krystal Biotech, Inc.

Krystal Biotech is a commercial-stage biotechnology company that develops and sells genetic medicines built on an engineered HSV-1 gene therapy platform. Its first approved product, VYJUVEK, treats dystrophic epidermolysis bullosa and is being commercialized in the U.S., Europe, and Japan, while the company also advances a pipeline of rare-disease and aesthetic skin programs.

42,9 %

52,6 %

+33,9 %

9.95

9.56

— Krystal Biotech, Inc.
%
Commercial product: VYJUVEK95% Approved topical gene therapy for dystrophic epidermolysis bullosa sold in the U.S., EU, and Japan.
Pipeline genetic medicines3% Clinical-stage product candidates targeting rare and serious diseases beyond DEB.
Aesthetic skin programs1% Preclinical programs under Jeune Aesthetics focused on aesthetic dermatology applications.
Platform and manufacturing capabilities1% Proprietary HSV-1 vector technology, purification processes, assays, and CGMP manufacturing.

Krystal Biotech sells primarily to patients with dystrophic epidermolysis bullosa through healthcare providers,...

  • DEB patients and caregiversprimary

    Buy VYJUVEK through the care pathway because it is the only approved corrective therapy for DEB and can be used in office or home settings.

  • Specialty clinicians and treatment centersprimary

    Prescribe and administer VYJUVEK for patients with severe dystrophic epidermolysis bullosa and manage ongoing treatment.

  • Specialty pharmacies and reimbursement intermediariesprimary

    Support dispensing, reimbursement approvals, and patient access, which directly affects commercial uptake.

  • Regional specialty distributorssecondary

    Buy and distribute VYJUVEK in markets outside the U.S., major EU countries, the UK, and Japan.

  • Research and development partners / future patientsemerging

    Not current revenue customers, but important for future pipeline commercialization and expansion into new indications.

The company is headquartered in Pittsburgh, Pennsylvania and operates as a global commercial-stage biotech with...

  • •Headquartered in Pittsburgh, Pennsylvania, United States
  • •U.S. launch began in 2023 and remains the core market
  • •Europe and Japan launches started in 2025
  • •Specialty distributors cover Central/Eastern Europe, Middle East, Turkey
  • •Wholly owned subsidiaries support commercialization in Europe and Japan

Krystal Biotech’s strategy is to maximize VYJUVEK adoption in DEB while expanding geographically through direct...

01
Globalize VYJUVEK commercializationshort-term

VYJUVEK is the company’s main revenue driver, so broader launch execution is central to growth.

02
Build a broader pipeline from the HSV-1 platformmedium-term

A second or third product would reduce concentration risk and extend the platform’s value.

03
Maintain manufacturing and quality control in-housemedium-term

Internal CGMP capacity supports supply reliability, product quality, and margin control.

The company is highly dependent on VYJUVEK, so any slower-than-expected adoption, reimbursement friction, safety issue,...

high

Dependence on VYJUVEK commercial success

Near-term revenue and future growth are substantially tied to one approved product.

Scope
Global commercial business
Materiality
high
high

International regulatory and market access execution

Approval, pricing, and reimbursement differ by country and can delay or limit uptake.

Scope
Europe, Japan, and distributor-led territories
Materiality
high
medium

Competitive pressure in gene therapy and DEB

Competitors may launch safer, cheaper, or more convenient therapies first.

Scope
DEB and adjacent rare disease markets
Materiality
medium
medium

Cybersecurity and third-party service disruption

A 2024 incident at a specialty pharmacy provider delayed reimbursement approvals and hurt revenue.

Scope
Commercial operations and patient access
Materiality
medium
medium

Clinical development failure

Pipeline candidates may not demonstrate efficacy or obtain approval, limiting diversification.

Scope
Pipeline programs
Materiality
medium
Revenue recognition and variable consideration
Can change reported sales and margins quarter to quarter
Quarterly launch timing and seasonality
Creates comparability issues across quarters and regions
Stock-based compensation
Affects reported operating loss and non-cash expense trends
Capitalized manufacturing facilities and depreciation
Influences gross margin, operating expense, and cash flow
Valuation allowance on deferred tax assets
Can materially affect tax expense and equity

CRISPR Therapeutics AG

CRSP · Biological Products, (No Diagnostic Substances)

Benitec Biopharma Inc.

BNTC · Pharmaceutical Preparations

ABEONA THERAPEUTICS INC.

ABEO · Pharmaceutical Preparations

CASTLE BIOSCIENCES INC

CSTL · Services-Medical Laboratories

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

BIOCRYST PHARMACEUTICALS INC

BCRX · Biological Products, (No Diagnostic Substances)

: 28/04/2026